山东鲁抗医药股份有限公司 关于向特定对象发行股票申请文件的审核问询函回复更新的提示性公告

Group 1 - The company received an inquiry letter from the Shanghai Stock Exchange regarding its application for a specific stock issuance [1][2] - The company, along with relevant intermediaries, conducted a thorough study and addressed the questions raised in the inquiry letter, making necessary revisions to the application documents [1][2] - The stock issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2] Group 2 - The company disclosed relevant documents on the Shanghai Stock Exchange website on June 18 and July 8, 2025, detailing the responses to the inquiry [1] - The company will continue to fulfill its information disclosure obligations based on the progress of the stock issuance matter [2] - Investors are advised to pay attention to investment risks associated with the uncertainty of the approval process [2]